# OnCo record nct04895358 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04895358/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04895358", "NCT04895358" ;
  schema:name "Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)"@en ;
  schema:alternateName "KEYNOTE-B49"@en ;
  schema:description "A phase 3 trial of Pembrolizumab, Doxorubicin and Capecitabine in advanced solid tumours, run by Merck Sharp & Dohme LLC, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04895358/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04895358> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2021-06-18" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/capecitabine/> ;
  onco:companies <https://onco.cc/companies/merck/> .